Answers are grounded in this paper and cite their sources.
Observational analysis identifies specific vascular and lymphatic adverse events in patients, indicating potential risks linked to antiangiogenic therapy.
Antiangiogenic therapy plays a critical role in cancer treatment. This study analyzed vascular and lymphatic adverse events linked to four FDA‐approved agents—aflibercept, bevacizumab, olaratumab, and ramucirumab—using WHO‐VigiAccess data. Disproportionality analysis (ROR and PRR) identified drug‐specific risks, focusing on hypertension, hemorrhage, thrombosis, and flushing, to inform safer and personalized clinical use.
No takes yet. Share an insight, caveat, or question.
Zu et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: